week 5 questions
writer please use single line spacing and respond to each with 400 words or less
Preparing the Assignment
Follow these guidelines when completing each component of the discussion. Contact your course faculty if you have questions.
General Instructions
This discussion represents the second step in a three-step discussion series where you will choose your pathophysiology adventure to analyze and present to the class. Students will continue to explore the disease process that was chosen in Week 2. In this step of the discussion series, you will describe the pathophysiology of your chosen condition from Week 2 and its manifestations, diagnosis, and lifespan considerations. You will also create your case study.
Include the following sections:
1. Application of Course Knowledge: Answer all questions/criteria with explanations and detail.
Describe the pathophysiology of the chosen condition. What is the conditionâ€s etiology, signs and symptoms, complications, and risk factors?
Discuss how the condition is diagnosed. What are relevant assessment findings, labs, and imaging studies?
Explain how the pathophysiology of the condition might differ across the lifespan. Does the condition manifest in pediatric, pregnant, breastfeeding, and older adult populations? How might the condition look different across the lifespan?
Create your case study based on the chosen condition (~ 1,000 words or less using bullet points and full sentences). Start with the diagnosis and work backward to develop a clinical scenario that leads to this diagnosis. Include the clientâ€s name, social background, symptoms, lab results, medical or surgical history, and other relevant details.
2. Integration of Evidence: Integrate relevant scholarly sources as defined by program expectations:
Cite a scholarly source in the initial post.
Cite a scholarly source in one faculty response post.
Cite a scholarly source in one peer post.
Accurately analyze, synthesize, and/or apply principles from evidence with no more than one short quote (15 words or less) for the week.
Include a minimum of two different scholarly sources per week. Cite all references and provide references for all citations.
3. Engagement in Meaningful Dialogue: Engage peers and faculty by asking questions and offering new insights, applications, perspectives, information, or implications for practice.
Peer Response: Respond to at least one peer on a condition other than the one you selected.
Faculty Response: Respond to at least one faculty post.
Communicate using respectful, collegial language and terminology appropriate to advanced nursing practice.
4. Professionalism in Communication: Communicate with minimal errors in English grammar, spelling, syntax, and punctuation. 
5. Reference Citation: Use current APA format to format citations and references free of errors. 
6. Wednesday Participation Requirement: Provide a substantive response to the graded discussion topic (not a response to a peer or faculty), by Wednesday, 11:59 p.m. MT of each week. 
7. Total Participation Requirement: Provide at least three substantive posts (one to the initial question or topic, one to a student peer, and one to a faculty question) on two different days during the week.  
Peer post/Shanese smith
Case Study: Sylvia Johnson
Diagnosis: Systemic Lupus Erythematosus with Renal Involvement (Lupus Nephritis)
Client and Social Background:
Sylvia Johnson is a 34-year-old African American woman who presents to her primary care provider with a three-month history of increasing fatigue, joint pain, intermittent low-grade fever, and a red rash across her cheeks that becomes more noticeable after sun exposure. Sylvia works full-time as a dental assistant, is married, and has two children. She reports no tobacco or illicit drug use and drinks alcohol occasionally. Her mother has a history of an autoimmune disorder. Sylvia reports that she has recently noticed swelling around her ankles and foamy urine.
Presenting symptoms and assessment findings:
Sylvia reports bilateral hand and knee pain with morning stiffness lasting approximately one hour. She describes profound fatigue despite adequate sleep and intermittent headaches. Physical examination reveals a malar rash across the cheeks and bridge of the nose, mild alopecia, tenderness and swelling of several proximal interphalangeal joints, and bilateral lower-extremity edema. Her blood pressure is 147/94 mmHg. No evidence of joint deformity is present.
Medical and surgical history:
Sylvia has no significant surgical history. She reports a history of migraine headaches but no previous renal disease, diabetes, or hypertension. She is not taking any prescription medications other than occasional ibuprofen for joint pain.
Laboratory findings:
Laboratory evaluation demonstrates hemoglobin of 10.8 g/dL, leukocyte count of 3,200/mm3, and platelet count of 135,000/mm3. Serum creatinine is elevated at 1.4 mg/dL, and urinalysis demonstrates 3+ protein, microscopic hematuria, and red blood cell casts. A urine protein-to-creatinine ratio is elevated. Antinuclear antibody (ANA) testing is strongly positive. Anti-double-stranded DNA (anti-dsDNA) antibodies are elevated, while complement levels are decreased, with low C3 and C4. These findings support an active systemic autoimmune process with renal involvement.
Diagnostic reasoning:
Sylviaâ€s diagnosis is based on the combination of constitutional, musculoskeletal, mucocutaneous, hematologic, and renal manifestations together with characteristic immunologic abnormalities. The 2019 EULAR/ACR classification framework uses a positive ANA as the entry criterion and then evaluates weighted clinical and immunologic domains, including hematologic, mucocutaneous, musculoskeletal, renal complement, antiphospholipid antibody, and SLE-specific antibody findings. Sylviaâ€s positive ANA, anti-dsDNA antibodies, low complement levels, inflammatory arthritis, malar rash, cytopenias, and renal abnormalities strongly support SLE. A kidney biopsy would be appropriate to determine the class and severity of lupus nephritis and guide treatment.
Pathophysiology, Etiology, and Risk Factors
Pathophysiology:
SLE is a systemic autoimmune disease characterized by a loss of self-tolerance. Genetic susceptibility interacts with environmental and hormonal factors, resulting in abnormal activation of the innate and adaptive immune systems. Increased cellular apoptosis and impaired clearance of cellular debris expose antigens to the immune system. These nuclear materials stimulate innate immune pathways, including type I interferon signaling. B and T lymphocytes become abnormally activated, resulting in production of autoantibodies such as ANA and anti-dsDNA antibodies. Type I interferon and autoantibodies targeting nucleic acids and nucleic-acid-binding proteins are important mediators of SLE pathogenesis (Crow et al., 2023)
Autoantibodies: Autoantibodies bind to nuclear antigens and form circulating immune complexes. These complexes can deposit in tissues, including the renal glomeruli, where they activate complement and inflammatory pathways. Complement activation recruits inflammatory cells and contributes to tissue injury. In lupus nephritis, immune-complex deposition and inflammation damage the glomerular filtration barrier, resulting in proteinuria, hematuria, hypertension, and declining renal function.
Etiology: The exact cause of SLE is multifactorial and not completely understood. Genetic predisposition, hormonal influences, environmental exposures, infections, ultraviolet radiation, smoking, and certain medications may contribute to disease development or exacerbation. The disease occurs when these factors interact with abnormalities in immune regulation.
Signs and symptoms:
Common manifestations include fatigue, fever, arthralgia or inflammatory arthritis, photosensitivity, malar or other cutaneous rashes, oral or nasal ulcers, alopecia, Raynaud phenomenon, lymphadenopathy, cytopenias, serositis, neurologic manifestations, and renal disease. Because SLE is systemic, manifestations may vary substantially between patients.
Risk factors:
Important risk factors include female sex, particularly during the reproductive years; family history of autoimmune disease; genetic susceptibility; certain racial and ethnic backgrounds; hormonal influences; ultraviolet exposure; smoking; and environmental triggers.
Potential complications:
Complications include lupus nephritis and chronic kidney disease, hypertension, cardiovascular disease, accelerated atherosclerosis, thrombosis associated with antiphospholipid antibodies, anemia and other cytopenias, neurologic disease, infection related to immune dysfunction or immunosuppressive therapy, osteoporosis, and pregnancy complications; severe renal or cardiovascular involvement can contribute significantly to morbidity and mortality.
Diagnosis and Relevant Testing:
There is no single laboratory test that independently establishes SLE. Diagnosis requires clinical assessment combined with laboratory findings and exclusion of alternative conditions.
ANA: A highly sensitive screening and classification test. A positive ANA is required as the entry criterion in the 2019 EULAR/ACR classification system.
Anti-dsDNA: More specific for SLE and particularly relevant when renal disease is present.
Anti-Smith antibodies: Highly specific for SLE.
Complement C3 and C4: Decreased levels may indicate active immune-complex disease because complement is consumed during immune activation.
CBC: May demonstrate anemia, leukopenia, lymphopenia, or thrombocytopenia.
Urinalysis: May demonstrate proteinuria, hematuria, and cellular casts in lupus nephritis.
Serum creatinine/eGFR: Used to evaluate renal function.
Urine protein-to-creatinine ratio: Helps quantify protein loss.
Antiphospholipid antibodies: Evaluate for increased thrombotic and pregnancy-related risk.
Kidney biopsy: When significant renal involvement is suspected, biopsy can identify the class and severity of lupus nephritis and help guide therapy.
Imaging: Not diagnostic of SLE but may be used to evaluate organ-specific manifestations, such as chest imaging for pleural disease or echocardiography for pericardial involvement.
Pathophysiology Across the Lifespan
Pediatric population: Childhood-onset SLE can be more aggressive than adult-onset disease. Children may experience greater renal, neurologic, and hematologic involvement and may have more cumulative organ damage over time. Consider growth, puberty, school attendance, psychosocial development, and medication adherence.
Pregnancy: SLE can become more difficult to manage during pregnancy because hormonal and immunologic changes may influence disease activity. Women with active disease, particularly active nephritis or uncontrolled hypertension, have increased risk for preeclampsia, fetal growth restriction, preterm birth, and pregnancy loss. Pregnancy planning is therefore important, and disease activity should ideally be controlled before conception.
Breastfeeding: Breastfeeding may be possible for many individuals with SLE, but medication selection is important because some immunosuppressive medications are incompatible with breastfeeding. The mother’s disease activity, treatment regimen, and infant safety must be evaluated collaboratively.
Older adults: Late-onset SLE may present differently from disease beginning during the reproductive years. Older adults may have less prominent malar rash or arthritis but may have greater constitutional, pulmonary, serosal, or neurologic manifestations. Diagnosis can be challenging because symptoms may overlap with other age-related conditions, and older adults may have more comorbidities and increased susceptibility to medication adverse effects.
Case Study Summary
Sylviaâ€s presentation demonstrates how SLE can progress from loss of immune tolerance to systemic inflammation and organ-specific injury. Her photosensitive malar rash, inflammatory arthritis, cytopenias, positive ANA and anti-dsDNA antibodies, low complement levels, proteinuria, hematuria, and elevated creatinine collectively support SLE with renal involvement. The renal findings are particularly important because immune-complex deposition within the glomeruli can activate complement and inflammatory pathways, producing lupus nephritis. This case illustrates the connection between cellular immunologic abnormalities and the clinical manifestations of SLE and demonstrates why early recognition of renal involvement is essential to prevent progressive kidney damage.
References:
Akhil, A., Bansal, R., Anupam, K., Tandon, A., & Bhatnagar, A. (2023). Systemic lupus erythematosus: Latest insight into etiopathogenesis. Rheumatology International, 43(8), 1381-1393. https://doi.org/10.1007/s00296-023-05346-xLinks to an external site.
Crow, M. K. (2023). Pathogenesis of systemic lupus erythematosus: Risks, mechanisms and therapeutic targets. Annals of the Rheumatic Diseases, 82(8), 999-1014. https://doi.org/10.1136/ard-2022-223741Links to an external site.
Faculty/Dr Hull post
Hi Jillian,
Thanks for your contributions to this week’s discussion! What are the signs and symptoms of duodenal ulcer? In comparison and in contrast, what are the symptoms of ulcerative colitis?
Thank you, Dr. Hull
